



July 28, 2022

To

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
Tel: 022 - 2272 1233 / 4  
Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783

ISIN: INE483I07010

**Sub: Intimation of the date of the Board Meeting for approval of the Financial Results for Q4 FY22, FY22 and Q1 FY23**

Pursuant to Regulation 50(1)(c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take on record that a meeting of the Board of Directors of Aragen Life Sciences Private Limited is scheduled to be held on **Wednesday, the 03<sup>rd</sup> August 2022**, inter alia, to consider and approve the following:

**1) Revised Standalone and Consolidated Financial Results of the Company for the Fourth Quarter (unaudited) and the Financial Year (audited) ended 31<sup>st</sup> March 2022.**  
Please refer the note below.

**2) Unaudited Standalone Financial Results of the Company for the Quarter ended 30<sup>th</sup> June 2022.**

**Note on requirement to revise the Financial Results for the quarter and the year ended 31<sup>st</sup> March 2022:**

As intimated by the Company to the stock exchange on 10<sup>th</sup> June 2022, the Company received the approval of the Composite Scheme of Arrangement between Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited, GVK Davix Research Private Limited and Aragen Life Sciences Private Limited, and their respective shareholders, by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide its Order dated 30<sup>th</sup> May 2022, certified copy of which was received by the Company on 7<sup>th</sup> June 2022. The Company filed the Order with the Registrar of Companies, Telangana on 1<sup>st</sup> July 2022, whereupon the parent company GVK Davix Technologies Private Limited amalgamated with the Company as of the Appointed Date 2<sup>nd</sup> April 2021. **This being a subsequent adjusting event as per the Standard of Auditing 560, the Company is required to revise the financial statements and results for the fourth quarter and the year ended 31<sup>st</sup> March 2022, to reflect the amalgamation.**

**For Aragen Life Sciences Private Limited**

**Ramakrishna Kasturi**

Company Secretary & Compliance Officer



Registered & Corporate Office  
Aragen Life Sciences Pvt. Ltd.  
(Formerly known as GVK Biosciences Pvt. Ltd.)  
28 A, IDA Nacharam, Hyderabad 500 076, India  
T: +91 40 6692 9999 F: +91 40 6692 9900  
W: aragen.com CIN: U74999TG2000PTC035826